A C Moses

3.8k total citations · 1 hit paper
49 papers, 3.1k citations indexed

About

A C Moses is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Physiology. According to data from OpenAlex, A C Moses has authored 49 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Endocrinology, Diabetes and Metabolism, 21 papers in Molecular Biology and 7 papers in Physiology. Recurrent topics in A C Moses's work include Growth Hormone and Insulin-like Growth Factors (19 papers), Metabolism, Diabetes, and Cancer (11 papers) and Thyroid Disorders and Treatments (8 papers). A C Moses is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (19 papers), Metabolism, Diabetes, and Cancer (11 papers) and Thyroid Disorders and Treatments (8 papers). A C Moses collaborates with scholars based in United States, Denmark and Canada. A C Moses's co-authors include J S Flier, Harold N. Rosen, Patricia Usher, S. L. Greenspan, George L. King, C. Ronald Kahn, Sheldon M. Buzney, Andrew Goodman, Jeffrey S. Flier and Robert D. Silver and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

A C Moses

48 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta.

1985 364 citations A C Moses et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A C Moses United States	27	1.4k	1.4k	427	427	379	49	3.1k
R. Bouillon Belgium	30	762 0.5×	840 0.6×	336 0.8×	432 1.0×	1.1k 2.8×	70	4.2k
Tripathi B. Rajavashisth United States	25	382 0.3×	1.4k 1.0×	654 1.5×	432 1.0×	303 0.8×	38	4.5k
Alan C. Moses United States	40	3.7k 2.6×	2.2k 1.6×	1.2k 2.8×	278 0.7×	626 1.7×	82	5.5k
Kay W. Colston United Kingdom	34	523 0.4×	1.0k 0.7×	140 0.3×	988 2.3×	1.1k 2.8×	59	3.8k
Subhash C. Kukreja United States	32	511 0.4×	1.1k 0.8×	285 0.7×	1.1k 2.6×	599 1.6×	93	3.4k
J. L. H. O’Riordan United States	34	494 0.4×	1.1k 0.8×	382 0.9×	814 1.9×	718 1.9×	102	4.0k
Paula H. Stern United States	37	664 0.5×	1.9k 1.4×	358 0.8×	1.4k 3.4×	566 1.5×	163	4.4k
Ruth McCracken United States	25	280 0.2×	1.3k 0.9×	276 0.6×	444 1.0×	405 1.1×	28	3.1k
Hollis A. Simmons United States	33	555 0.4×	2.0k 1.4×	214 0.5×	1.6k 3.8×	928 2.4×	52	4.0k
Charles K. Lumpkin United States	34	367 0.3×	1.8k 1.3×	320 0.7×	635 1.5×	565 1.5×	69	3.4k

Countries citing papers authored by A C Moses

Since Specialization

Citations

This map shows the geographic impact of A C Moses's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A C Moses with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A C Moses more than expected).

Fields of papers citing papers by A C Moses

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A C Moses. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A C Moses. The network helps show where A C Moses may publish in the future.

Co-authorship network of co-authors of A C Moses

This figure shows the co-authorship network connecting the top 25 collaborators of A C Moses. A scholar is included among the top collaborators of A C Moses based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A C Moses. A C Moses is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moses, A C, et al.. (2025). Prevalence and factors associated with puerperal sepsis among postnatal women at a Tertiary Referral Hospital in Western Uganda. PLoS ONE. 20(8). e0311708–e0311708.

Moses, A C, Paul W. Blair, Peter Waitt, et al.. (2021). Optimizing Highly Infectious Disease Isolation Unit Management: Experiences From the Infectious Diseases Isolation and Research Unit, Fort Portal, Uganda. Disaster Medicine and Public Health Preparedness. 17. e72–e72. 2 indexed citations

Daniels, Gilbert H., László Hegedüs, Steven P. Marso, et al.. (2015). LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the L iraglutide E ffect and A ction in D iabetes: E valuation of cardiovascular outcome R esults ( LEADER ) trial: preliminary observations. Diabetes Obesity and Metabolism. 17(5). 477–486. 17 indexed citations

Zinman, Bernard, Wolfgang E. Schmidt, A C Moses, N. Lund, & Stephen Gough. (2011). Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programme. Diabetes Obesity and Metabolism. 14(1). 77–82. 91 indexed citations

Zinman, Bernard, John B. Buse, A Falahati, A C Moses, & S Gough. (2009). Liraglutide More Effectively Achieves a Composite Endpoint for A1C, SBP and Weight Change Than Other Diabetes Therapies. Diabetes. 58. 8 indexed citations

Moses, A C, P. Raskin, & Naum Khutoryansky. (2008). Does serum 1,5‐anhydroglucitol establish a relationship between improvements in HbA_1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. Diabetic Medicine. 25(2). 200–205. 12 indexed citations

Gavrila, Alina, William Hsu, Sotirios Tsiodras, et al.. (2005). Improvement in Highly Active Antiretroviral Therapy--Induced Metabolic Syndrome by Treatment with Pioglitazone but Not with Fenofibrate: A 2 x 2 Factorial, Randomized, Double-Blinded, Placebo-Controlled Trial. Clinical Infectious Diseases. 40(5). 745–749. 43 indexed citations

Clemmons, David R., A C Moses, Andreas Sommer, et al.. (2005). Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Hormone & IGF Research. 15(4). 265–274. 60 indexed citations

Rosen, Harold N., A C Moses, Jeffrey R. Garber, et al.. (2000). Serum CTX: A New Marker of Bone Resorption That Shows Treatment Effect More Often Than Other Markers Because of Low Coefficient of Variability and Large Changes with Bisphosphonate Therapy. Calcified Tissue International. 66(2). 100–103. 237 indexed citations

10.

Rosen, Harold N., A C Moses, Jeffrey R. Garber, et al.. (1998). Utility of Biochemical Markers of Bone Turnover in the Follow-up of Patients Treated with Bisphosphonates. Calcified Tissue International. 63(5). 363–368. 63 indexed citations

11.

Mantzoros, C. S., et al.. (1995). Imaging of the sella in the syndrome of inappropriate secretion of antidiuretic hormone. Journal of Internal Medicine. 237(2). 181–185. 6 indexed citations

12.

Rosen, Harold N., et al.. (1994). Subregion analysis of the rat femur: A sensitive indicator of changes in bone density following treatment with thyroid hormone or bisphosphonates. Calcified Tissue International. 55(3). 173–175. 8 indexed citations

13.

Rosen, Harold N., et al.. (1994). Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcified Tissue International. 54(1). 26–29. 148 indexed citations

14.

Flier, Jeffrey S., David E. Moller, A C Moses, et al.. (1993). Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance.. The Journal of Clinical Endocrinology & Metabolism. 76(6). 1533–1541. 57 indexed citations

15.

Taboga, Claudio, Elizabeth Salamon, A C Moses, et al.. (1990). Biological Activity of Nasally Administered Insulin in Normal Subjects. Hormone and Metabolic Research. 22(3). 170–174. 35 indexed citations

16.

Moses, A C, Harold N. Rosen, David E. Moller, et al.. (1990). A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia.. Journal of Clinical Investigation. 86(6). 2025–2033. 56 indexed citations

17.

Mitchell, M. L., Rosalie J. Hermos, Mordechai Feingold, & A C Moses. (1989). The Relationship of Insulin-Like Growth Factor-I to Total Thyroxine in Normal and Low Birth Weight Infants. Pediatric Research. 25(4). 336–338. 5 indexed citations

18.

Maciel, Rui M. B., et al.. (1988). Demonstration of the production and physiological role of insulin-like growth factor II in rat thyroid follicular cells in culture.. Journal of Clinical Investigation. 82(5). 1546–1553. 70 indexed citations

19.

Mitchell, M. L., Rosalie J. Hermos, & A C Moses. (1987). SOMATOMEDIN‐C/INSULIN‐LIKE GROWTH FACTOR‐1 IN INFANTS WITH CONGENITAL HYPOTHYROIDISM DURING THE FIRST WEEK OF LIFE. Clinical Endocrinology. 27(5). 625–628. 5 indexed citations

20.

Rechler, Matthew M., Howard J. Eisen, Olga Z. Higa, et al.. (1979). Characterization of a somatomedin (insulin-like growth factor) synthesized by fetal rat liver organ cultures.. Journal of Biological Chemistry. 254(16). 7942–7950. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact